IP Library Granted Patent US 7,232,436
Granted Patent B2
US 7,232,436 · App. 11/033,967 · Granted Jun 19, 2007

Closed loop control for intrastromal wavefront-guided ablation with fractionated treatment program

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,232,436
App. No.
11/033,967
Granted
Jun 19, 2007
Kind
B2
Abstract

A closed-loop control system for altering the optical characteristics of a patient's cornea includes an algorithm for predicting the shape of the cornea after one or more gas bubbles resulting from intrastromal photoablation have collapsed. Patient data can be used as an input for the algorithm, which is then run to prepare an initial treatment plan for a corneal alteration. The initial plan typically includes a plurality of intrastromal photoablation locations and corresponding ablation energies. After photoablation of plan location(s) and before the resulting bubbles collapse, a real-time wavefront shape for light passing through the cornea is measured. The wavefront is then used in the algorithm to predict a post bubble collapse cornea shape and to generate an updated treatment plan. The procedure then continues by ablating location(s) identified in the updated treatment plan. Wavefront measurement and plan updating can be repeated as many times as desired.

Claims (49)

1. A method for altering the optical characteristics of a patient's cornea, said method comprising the steps of:

preparing an algorithm to predict a shape for the cornea after collapse of a gas bubble resulting from an intrastromal photoablation;

inputting patient data into said algorithm to prepare an initial treatment plan to alter the optical characteristics of the patient's cornea, said initial treatment plan including at least one photoablation location;

photoablating a location in the initial treatment plan to create a gas bubble;

measuring a wavefront shape for light passing through the cornea after said photoablation step and before said gas bubble collapses;

processing said algorithm with said measured wavefront shape to generate an updated treatment plan, said updated treatment plan including at least one photoablation location; and

using a laser beam to photoablate tissue at a location in the updated treatment plan.

2. A method as recited in claim 1 wherein said method further comprises the steps of:

measuring a stress distribution in the patient's cornea; and

inputting data corresponding to said measured stress distribution into said algorithm to predict a post bubble collapse wavefront shape.

3. A method as recited in claim 1 wherein the intrastromal photoablation causes water evaporation and said method comprises the step of inputting data corresponding to said water evaporation in predicting a post bubble collapse wavefront shape.

4. A method as recited in claim 1 wherein the intrastromal photoablation causes tissue expansion and said method comprises the step of inputting data corresponding to said tissue expansion in predicting a post bubble collapse wavefront shape.

5. A method as recited in claim 1 wherein the intrastromal photoablation causes extension of collagen fibers and said method comprises the step of inputting data corresponding to said extension of collagen fibers in predicting a post bubble collapse wavefront shape.

6. A method as recited in claim 1 wherein the intrastromal photoablation causes collapse of tissue and said method comprises the step of inputting data corresponding to said collapse of tissue in predicting a post bubble collapse wavefront shape.

7. A method as recited in claim 1 wherein said measuring step measures said wavefront shape using light that has not passed through a gas bubble.

8. A system for altering the optical characteristics of a patient's cornea, said system comprising:

a software equipped computer for processing an algorithm to predict a shape for the cornea after collapse of a gas bubble resulting from an intrastromal photoablation;

a means for inputting patient data into said computer for use with said algorithm to prepare an initial treatment plan, said initial treatment plan including at least one photoablation location to alter the optical characteristics of the patient's cornea;

a laser means responsive to said computer for photoablating a location in the initial treatment plan to create a gas bubble;

a means for measuring a wavefront shape for light passing through the cornea after photoablation of said location and before a resulting gas bubble collapses;

a means for inputting said measured wavefront shape into said algorithm to generate an updated treatment plan, said updated treatment plan including at least one photoablation location; and

a means responsive to said computer to configure said laser means to photoablate a location in the updated treatment plan.

9. A system as recited in claim 8 wherein said laser means generates a pulsed laser beam.

10. A system as recited in claim 8 wherein said measuring means is a Hartmann-Shack sensor unit.

11. A system as recited in claim 8 further comprises:

means for measuring a stress distribution in the patient's cornea; and

means for inputting data corresponding to said measured stress distribution into said algorithm to predict a post bubble collapse wavefront shape.

12. A system as recited in claim 8 wherein the intrastromal photoablation causes water evaporation and said system further comprises a means for inputting data corresponding to said water evaporation into said algorithm.

13. A system as recited in claim 8 wherein the intrastromal photoablation causes tissue expansion and said system further comprises a means for inputting data corresponding to said tissue expansion into said algorithm.

14. A system as recited in claim 8 wherein the intrastromal photoablation causes extension of collagen fibers and said system further comprises a means for inputting data corresponding to said extension of collagen fibers into said algorithm.

15. A system as recited in claim 8 wherein the intrastromal photoablation causes collapse of tissue and said system further comprises a means for inputting data corresponding to said collapse of tissue into said algorithm.

16. A method for correcting an optical deficiency in a cornea of an eye, said method comprising the steps of:

directing a laser beam to a focal point at a subsurface location in the cornea to photoablate stromal tissue at the location;

scanning the focal point to successive locations to photoablate stromal tissue at each successive location and temporarily induce stresses in tissue surrounding the locations;

allowing a time period greater than one day to elapse without photoablation after said scanning step, said time period being of sufficient duration to allow said stressed tissue to relax to a substantially stable condition; and thereafter

photoablating additional stromal tissue.

17. A method as recited in claim 16 wherein said optical deficiency is undercorrected after said scanning step.

18. A method as recited in claim 16 wherein said photoablating additional stromal tissue step comprises the sub-steps of:

directing a laser beam to a focal point at a subsurface location in the cornea to photoablate stromal tissue at the location;

scanning the focal point to successive locations to photoablate stromal tissue at each successive location and temporarily induce stresses in tissue surrounding the locations;

allowing a predetermined time period to elapse without photoablation after said scanning step, said time period being of sufficient duration to allow said stressed tissue to relax to a substantially stable condition; and thereafter

photoablating additional stromal tissue.

19. A method as recited in claim 16 wherein said directing and scanning steps comprise the sub-steps of:

preparing an algorithm to predict a shape for the cornea after collapse of a gas bubble resulting from an intrastromal photoablation;

inputting patient data into said algorithm to prepare an initial treatment plan to alter the optical characteristics of the patient's cornea, said initial treatment plan including at least one photoablation location;

photoablating a location in the initial treatment plan to create a gas bubble;

measuring a wavefront shape for light passing through the cornea after said photoablation step and before said gas bubble collapses;

processing said algorithm with said measured wavefront shape to generate an updated treatment plan, said updated treatment plan including at least one photoablation location; and

using a laser beam to photoablate tissue at a location in the updated treatment plan.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →